Breaking the Impasse
Small cell lung cancer (SCLC) is an aggressive malignancy and carries a poor prognosis with limited effective treatments in the advanced setting. SCLC is characterized by a high tumor mutation burden and alterations in Notch signaling and DNA damage repair pathways, providing rationale for the use of immunotherapy and targeted therapies. Immunotherapies have led to the most significant advances in treating SCLC in decades, and several promising targeted approaches have emerged from the increased understanding of the biology of SCLC. However, responses to these novel approaches are far from universal, and efforts to refine these therapies are ongoing.
Source: Clinics in Chest Medicine - Category: Respiratory Medicine Authors: Andreas Saltos, Scott Antonia Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Gastroschisis Repair | Immunotherapy | Lung Cancer | Respiratory Medicine | Small Cell Lung Cancer